Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info

Executive Summary

A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.


Related Content

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products
Biosimilar Battle Plans: US Supreme Court Seeks Solicitor General's Views On Zarxio
Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Neulasta Biosimilar: Smooth Patent Dance, Stumble On Launch Notification


Related Companies